Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfolio to 100 drugs by 2040. Sandoz targets mid-to-high single-digit sales growth from 2025 to 2030. Its net sales targets exclude potential contributions from generic GLP-1 drugs. Sandoz will invest an additional $300 million in a Slovenian biosimilar manufacturing facility.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.